residual tumors การใช้

• Unfortunately, the patient died several weeks afterwards from a residual tumor.
• The images also may show a residual tumor left behind after lumpectomy surgery.
• Doctors typically use an electric needle that destroys the residual tumor and controls bleeding.
• In these cases the residual tumor should be followed for risk of growth ( approximately 35 % ).
• The growth of the residual tumor also is contributing to Congressman Tejeda's speech impairment, " the statement read.
• Following resection of infratentorial ependymomas, residual tumor is more likely in lateral versus medial tumors, classified radiologically pre-operatively.
• Spanish and German doctors, in 1905 and 1915 respectively, used intraoperative radiation therapy ( IORT ) in an attempt to eradicate residual tumors left behind after surgical resection.
• If a significant amount of residual tumor is left in the neck, external radiotherapy has been indicated and has proven useful especially in those cases when the residual tumor does not take up radioiodine.
• If a significant amount of residual tumor is left in the neck, external radiotherapy has been indicated and has proven useful especially in those cases when the residual tumor does not take up radioiodine.
• Another major limitation with only using ctDNA levels to detect tumor burden is that ctDNA can only predict residual tumor, it cannot tell you where the tumor or tumors are located within the body.
• Often the lining of the tumor connected to the brain stem or parts difficult to " peel " away are left behind leaving residual tumor after surgery, this can contribute to the risk of regrowth.
• It has been found that levels of ctDNA in plasma significantly correlate with tumor volume as compare with medical imaging ( CT, PET and MRI ) ., Detection of ctDNA can predict residual tumor or imminent relapse, in some cases even better than medical imaging and current methods.
• Biovest submitted its MAA following the successful completion and long-term follow-up of two Phase 2 clinical trials and of one multi-center, randomized, Phase 3 clinical trial ( all conducted in partnership with the U . S . National Cancer Institute ) in which BiovaxID demonstrated it could induce powerful anti-tumor immune responses, eradicate residual tumor cells from patients blood following chemotherapy, and improve the duration of complete remissions by a median of 15.4 months relative to control.